About Clinics and Laboratories

We live in amazing time: in the period of the newest technologies development, including biotechnologies, flourishing of cellular (also called cell) and tissue therapy, that help to manage diseases, which were incurable before.

Stem cells are one of the most astonishing discoveries of modern medicine, which is able to alter concept of treatment of many diseases and give people the main things — youth, strength, longevity and sometimes the only chance to survive.

What is so interesting about stem cells? Explorations of stem cells extended our knowledge about the way how our organism develops from a single cell and how new healthy cells in adult organism replace injured cells.

Study of stem cells characteristics opened broad possibilities for cellular therapy application in treatment of many severe diseases. Stem cells are progenitors and precursors for all types of cells and tissues in organism. They have unique biological potential. In transplantation donor’s stem cells are not recognized as “foreign” and may fulfill their vital functions. In response to signal molecules appearance they migrate into center of injure where they launch reparative (restoration) processes and also they differentiate into appropriate specialized cells and tissues. As a result, the effect of injured tissues and organs restoration is achieved.

SmartCell Center, scientific-research, specialized medical-diagnostic facility, that became the base for clinic, was founded in 2003, in Kiev. Specialists of the SmartCell Center developed and introduced into medical practice the newest scientific achievements in the area of cell technologies, cryomedicine and non-medicinal methods of treatment. Unique personal methodics of stem cells treatment are protected with numerous patents and certificates of recognition. They have obtained international acknowledgement and have demonstrated high effectiveness in clinical practice.

In 2014, the Clinic of the SmartCell Center among a few medical institutions of Ukraine successfully passed prestigeous international certification ISO 9001:2008. Certificate ISO 9001:2008 was awarded to the SmartCell Center by certifying company TÜV Rheinland / LGA InterCert (Germany) after thorough audit towards compliance of the quality management system of the Clinic to the requirements of international standard.

International certificate ISO 9001:2008 provides additional guarantees of the highest quality services delivered to the patients of the Institute Clinic.

The main direction of Clinic activity are:

• treatment with stem cells of the following diseases (stroke,   diabetes mellitus, joints diseases, cardio-vascular diseases, hepatitis, liver cirrhosis, rehabilitation after chemotherapy and others), where traditional therapy is not effective;
• anti-aging therapy and rejuvenation of the organism;
• cosmetology with placenta extract application.

Clinic plays an important role in the successful development of cellular therapy. Efficiency of the treatment depends on specialists’ professional skills, their responsibility, and also on the technologies, with which the medical facility is equipped.

Our clinic is equipped with modern instruments and has all the possibilities for out-patient and in-patient treatment, and also for diagnostic examinations and rehabilitation measures.

Specialists deliver highly professional medical care in diagnostics, treatment and rehabilitation of patients with complex diseases of any etiology, when traditional methods of treatment are not effective. Clinic has all the medical technologies, which allow to diagnose during the shortest period of time and to determine the scope of patient’s problems.

We present to your attention by far not complete list of diseases, that are treated with substantial success, using cellular technologies, developed in the  Centers:

• diseases of the central and peripheral nervous system: strokes, rehabilitation after strokes and craniocerebral traumas; 
  
• endocrine diseases: insulin-independent diabetes, complications of insulin-dependent diabetes and insulin-independent diabetes, hypothyroidism;
• cardio-vascular diseases: ischemic heart disease, heart failure, cardiomyopathies;
• gastro-intestinal diseases: liver cirrhosis, infectious and toxic hepatitis, consequences of B and C hepatitis, pancreatitis, stomach and duodenal ulcer;
• diseases of musculoskeletal system: arthritis, arthrosis, spinal osteochondrosis, hip joint dysplasia, traumas and also trauma consequences;
• immunodeficiency condition after chemotherapy course in cancer patients treatment;
• urogenital diseases: prostatitis, potency disorders, disorders of reproductive function in men and women;

Curative and sanitation Programs of the Clinics propose not only effective treatment of complex chronic diseases, but aging prophylaxis and rejuvenation. Anti-aging therapy with the application of the stem cells and placenta extract preparation, that is developed by the specialists of the Clinics, allows to interrupt aging processes and to gain body restoration for younger and more active functional level.

Our International Presence: Clinics and Official Offices

We operate through two legal official international offices and clinical locations, strategically positioned in Ukraine and Bulgaria, each functioning as a fully independent regenerative medicine center.

Ukraine ( Kyiv): A Large Multidisciplinary Medical and Research Hub

Our Ukrainian location is based within a large hospital complex, allowing close collaboration with multiple university clinics, academic institutions, and specialized medical departments. This infrastructure provides access to a wide spectrum of clinical expertise, diagnostic capabilities, and translational research opportunities.

Key features of our Ukrainian center include:

• A fully equipped stem cell clinic
• A licensed cryobank
• An advanced cell processing laboratory
• A dedicated Research and Protocol Development Department

The Ukrainian center plays a central role in scientific research, clinical protocol development, and long-term outcome analysis, making it a cornerstone of our entire international network.

Bulgaria( Sofia): A European Clinical and Cryopreservation Center

Our Bulgarian office and clinic serve as an important European gateway for patients from the EU, Middle East, and other regions. This location integrates:

• A modern regenerative medicine clinic
• A cryobank compliant with European standards
• A laboratory specializing in cell preparation, storage, and distribution

The Bulgarian center focuses on clinical application, patient coordination, and follow-up care, working closely with the Ukrainian research division to implement individualized protocols.

Integrated Infrastructure: Clinics, Cryobanks, and Laboratories

One of the defining strengths of our organization is the full vertical integration of regenerative medicine services.

Clinical Facilities

Each clinical location is designed to provide:

• Advanced diagnostics
• Inpatient and outpatient regenerative procedures
• Multidisciplinary medical consultations
• Continuous monitoring during and after therapy

Cryobanking Capabilities

Our cryobanks ensure:

• Long-term storage of autologous and donor-derived cells
• Strict temperature control and quality assurance
• Traceability and safety at every stage of cell handling
• Availability of cells for repeat or staged therapies

Cell Processing Laboratories

Our laboratories perform:

• Isolation and expansion of stem cells
• Differentiation into specialized cell types
• Quality control, sterility testing, and viability assessment
• Preparation of intracellular and extracellular biologic products

This integrated model allows full control over the therapeutic process—from cell sourcing to patient follow-up.

Research and Protocol Development Department (Ukraine)

A unique feature of our organization is the Research and Protocol Development Department, located in Ukraine due to the size of the hospital and its collaboration with university medical centers.

Role of the Research Department

The department is responsible for:

• Analyzing clinical outcomes
• Developing disease-specific treatment protocols
• Optimizing cell combinations and dosages
• Studying long-term safety and efficacy
• Integrating new scientific findings into clinical practice

Collaboration with Universities and Clinics

Through partnerships with university hospitals, the department participates in:

• Translational research projects
• Clinical observations and registries
• Comparative analysis of different cell types
• Development of personalized regenerative strategies

This academic integration ensures that our protocols are data-driven, continuously evolving, and clinically grounded.

Scientific and Clinical Leadership in Stem Cell Therapy: Ukraine and Bulgaria

Ukraine has played a pioneering role in the development of stem cell science and regenerative medicine in Eastern Europe and globally. Fundamental research involving multiple types of stem and progenitor cells has been conducted at the academic and scientific level in Ukraine since 1985, long before cell therapy entered widespread clinical discussion in many countries. This early scientific foundation enabled the country to establish a structured and legally regulated framework for translational and clinical applications of cellular technologies.

A major milestone was achieved in 1999, when the Parliament of Ukraine adopted the Law of Ukraine on the Transplantation of Organs and Other Anatomical Materials to Humans. This legislation formally regulated the medical use of fetal-derived, umbilical, and other stem cell types for the treatment of severe and life-threatening conditions. Importantly, the law defined the introduction of stem cells into the human body as a form of transplantation, with the cells themselves classified as biological grafts. Since the adoption of this framework, dozens of preclinical studies and clinical trials have been conducted to evaluate the safety, feasibility, and therapeutic potential of stem cell transplantation across a wide range of indications.

Building on this long-standing regulatory and scientific background, our organization has become one of the recognized pioneers in cell therapy, with more than 37 years of continuous experience in the development and clinical application of cryopreserved, tissue-specific stem and progenitor cells of various origins. Our expertise spans the entire lifecycle of cellular products—from tissue procurement and cell isolation to cryopreservation, quality control, and clinical delivery.

Largest Cell Banking Infrastructure and Global Clinical Collaboration

We operate one of the largest and most advanced cell banking infrastructures in Ukraine, with parallel clinical and biotechnological facilities in Bulgaria, allowing us to serve patients across Europe, the Middle East, Asia, and North America. Our biobanking and cell distribution programs have successfully provided biological materials and individualized cellular therapies to patients from Poland, Israel, the United States, China, the United Arab Emirates, Turkey, Germany, and other countries.

Our work is conducted within the framework of international medical and scientific collaboration. On a legal and institutional basis, we cooperate with leading global medical centers, including Charité – Universitätsmedizin Berlin, Sheba Medical Center (Israel), Munich University Hospital, and Mayo Clinic (USA). These collaborations support knowledge exchange, protocol development, and alignment with international clinical standards.

Regulatory Compliance Across Jurisdictions

Stem cell banking and clinical application are regulated differently across countries, and our operations are designed to comply with both national and international regulatory requirements.

In the United States, umbilical cord blood banking is strictly supervised by the Food and Drug Administration (FDA), which also regulates the clinical use of certain stem cell products for specific indications. Additionally, states such as New York, New Jersey, and California require specialized accreditation for cord blood banks; without such accreditation, a biobank is not legally permitted to operate.

Within the European Union, cord blood and tissue banks are coordinated and supervised through international regulatory frameworks, including NetCord, an organization supported by the European Parliament. NetCord oversees compliance, quality standards, and ethical practices while also promoting public awareness of umbilical cord blood banking.

In Ukraine and Bulgaria, stem cell and tissue banking activities are regulated through licensing systems established by the Ministries of Health, requiring strict adherence to defined technical, medical, and ethical standards. Only facilities that meet these requirements are authorized to perform cell and tissue preservation, processing, and clinical use.

Patented Technologies and Peer-Reviewed Scientific Output

All of our core technologies are patented and protected by intellectual property rights. Our scientific developments and clinical findings are actively published in respected national and international peer-reviewed journals, including Cell Biology and Translational Medicine, MDPI journals, Oxford University Press publications, World Journal of Stem Cells, Life Sciences, and other authoritative scientific outlets.

This publication activity reflects our commitment to transparency, reproducibility, and integration into the global scientific community.

National and International Scientific Expertise

Our consulting and advisory board includes leading experts from the Ministry of Health and the National Academy of Sciences of Ukraine, as well as senior researchers and clinicians from specialized research institutes. Through partnerships with major Ukrainian and Bulgarian research centers, we actively contribute to the advancement of regenerative medicine, translational research, and evidence-based clinical protocols.

Membership in International Scientific Societies

We are proud members of key international professional organizations, including:

• International Society for Cell & Gene Therapy (ISCT)
• International Placenta Stem Cell Society (IPLASS)
• International Society for Stem Cell Research (ISSCR)
• International Federation of Placental Research Associations (IFPA)

These memberships ensure ongoing alignment with global scientific standards, ethical guidelines, and emerging best practices.

Certified Quality Management and Operational Excellence

Our operations are governed by the ISO 9001:2015 international quality management system, which enables continuous monitoring and optimization of both medical services and technological processes. Independent audits confirming compliance with ISO standards have been conducted by TÜV Rheinland / LGA InterCert (Germany), one of the world’s leading certification bodies.

Broad Spectrum of Stem Cell Types and Advanced Differentiation Potential

Our clinics operate across the full spectrum of modern cellular and regenerative medicine, working with virtually all clinically relevant types of cells and cellular materials. These include autologous and allogeneic stem and progenitor cells derived from umbilical cord blood, umbilical cord tissue (Wharton’s jelly), bone marrow, adipose tissue, peripheral blood, dermal and epithelial tissues, as well as fetal-derived cell populations where legally permitted. In addition, we utilize lineage-committed and tissue-specific cells such as neural progenitors, neurons, oligodendrocytes, astrocytes, chondrocytes, myoblasts, hepatocytes, endothelial and microvascular cells, allowing targeted interventions for neurological, musculoskeletal, cardiovascular, hepatic, and systemic disorders. This comprehensive cellular portfolio enables precise selection of biological products based on disease pathophysiology, stage, and individual patient characteristics.

A key component of our platform is the ability to cultivate and expand narrowly differentiated and induced cell populations under controlled laboratory conditions. Using advanced cell culture systems, we generate induced pluripotent stem cells (iPSC) from patient-derived somatic cells, followed by directed differentiation into specific neural, glial, mesenchymal, or epithelial lineages. This approach allows for personalized, genetically matched therapies with reduced immunological risk. In parallel, we apply genetic screening, quality control, and—where scientifically justified—targeted gene modulation or correction technologies to optimize cellular function, stability, and therapeutic potential. These processes are conducted in compliance with international biosafety, ethical, and regulatory standards, ensuring reproducibility and clinical reliability.

Beyond whole-cell therapies, our clinical and research programs actively incorporate intra- and extracellular biological products, recognizing their central role in regenerative signaling. This includes the therapeutic use of exosomes, extracellular vesicles, secretomes, growth factors, cytokines, microRNAs, mitochondrial fractions, and other intracellular derivatives that mediate paracrine and immunomodulatory effects. These acellular and subcellular components are used both as standalone biologic therapies and in combination with cellular transplantation to enhance tissue repair, modulate inflammation, promote angiogenesis, support neuroplasticity, and activate endogenous regeneration mechanisms. By integrating cell-based, gene-based, and cell-free regenerative strategies, our clinics cover all major directions of contemporary cell therapy, offering a scientifically grounded, multimodal approach to complex and chronic diseases.